Psychemedics Stock Performance
| PMD Stock | USD 2.33 0.01 0.43% |
Psychemedics has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 0.0756, which implies not very significant fluctuations relative to the market. As returns on the market increase, Psychemedics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Psychemedics is expected to be smaller as well. Psychemedics right now holds a risk of 0.64%. Please check Psychemedics kurtosis, and the relationship between the downside variance and day median price , to decide if Psychemedics will be following its historical price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Psychemedics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound primary indicators, Psychemedics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
Five Day Return 0.43 | Year To Date Return (30.97) | Ten Year Return (84.49) | All Time Return (81.46) |
Last Split Factor 1:4 | Dividend Date 2023-06-08 | Ex Dividend Date 2023-05-24 | Last Split Date 2002-08-01 |
1 | PMD Device Solutions RespiraSense Technology Demonstrates Capability in Predicting 7-Day Mortality | 09/17/2024 |
2 | Psychemedics Releases First-Ever Education Insights Report Uncovering Drug Trends in Educational Institutions Through Hair Testing | 09/26/2024 |
3 | Acquisition by Kamin Peter of 627 shares of Psychemedics at 6.52 subject to Rule 16b-3 | 09/30/2024 |
4 | PMD Device Solutions Restructures to Focus Resources on Global Sales Expansion | 10/07/2024 |
5 | Bulletin from the Extraordinary General Meeting in PMD Device Solutions AB | 10/29/2024 |
6 | Psychemedics Third Quarter 2024 Earnings US0.091 loss per share | 11/15/2024 |
7 | PMD Device Solutions Announces Delay to Q3 2024 Quarterly Report | 11/20/2024 |
| Begin Period Cash Flow | 4.8 M |
Psychemedics |
Psychemedics Relative Risk vs. Return Landscape
If you would invest 230.00 in Psychemedics on August 31, 2024 and sell it today you would earn a total of 3.00 from holding Psychemedics or generate 1.3% return on investment over 90 days. Psychemedics is generating 0.0223% of daily returns assuming volatility of 0.6419% on return distribution over 90 days investment horizon. In other words, 5% of stocks are less volatile than Psychemedics, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Psychemedics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Psychemedics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Psychemedics, and traders can use it to determine the average amount a Psychemedics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0347
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PMD |
Estimated Market Risk
| 0.64 actual daily | 5 95% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Psychemedics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Psychemedics by adding it to a well-diversified portfolio.
Psychemedics Fundamentals Growth
Psychemedics Stock prices reflect investors' perceptions of the future prospects and financial health of Psychemedics, and Psychemedics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Psychemedics Stock performance.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 13.97 M | ||||
| Shares Outstanding | 5.89 M | ||||
| Price To Earning | 92.08 X | ||||
| Price To Book | 2.53 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 22.1 M | ||||
| Gross Profit | 9.29 M | ||||
| EBITDA | (251 K) | ||||
| Net Income | (4.15 M) | ||||
| Cash And Equivalents | 1.79 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 2.3 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 2.06 X | ||||
| Book Value Per Share | 1.15 X | ||||
| Cash Flow From Operations | (1.48 M) | ||||
| Earnings Per Share | (0.51) X | ||||
| Market Capitalization | 13.79 M | ||||
| Total Asset | 12.33 M | ||||
| Retained Earnings | (16.77 M) | ||||
| Working Capital | 2.1 M | ||||
| Current Asset | 8.46 M | ||||
| Current Liabilities | 3.56 M | ||||
About Psychemedics Performance
By analyzing Psychemedics' fundamental ratios, stakeholders can gain valuable insights into Psychemedics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Psychemedics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Psychemedics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.38) | (0.36) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (0.62) | (0.59) |
Things to note about Psychemedics performance evaluation
Checking the ongoing alerts about Psychemedics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Psychemedics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 22.1 M. Reported Net Loss for the year was (4.15 M) with profit before taxes, overhead, and interest of 9.29 M. | |
| Psychemedics has about 1.79 M in cash with (1.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Psychemedics has a poor financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from accesswire.com: PMD Device Solutions Announces Delay to Q3 2024 Quarterly Report |
- Analyzing Psychemedics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Psychemedics' stock is overvalued or undervalued compared to its peers.
- Examining Psychemedics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Psychemedics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Psychemedics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Psychemedics' stock. These opinions can provide insight into Psychemedics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Psychemedics Stock analysis
When running Psychemedics' price analysis, check to measure Psychemedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psychemedics is operating at the current time. Most of Psychemedics' value examination focuses on studying past and present price action to predict the probability of Psychemedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psychemedics' price. Additionally, you may evaluate how the addition of Psychemedics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |